NOBELPHARMA CEASING 3.0 mm BRANEMARK ENDOSSEOUS IMPLANT U.S. SHIPMENTS
This article was originally published in The Gray Sheet
Executive Summary
NOBELPHARMA CEASING 3.0 mm BRANEMARK ENDOSSEOUS IMPLANT U.S. SHIPMENTS following receipt of a March 7 FDA warning letter. Although voluntarily halting U.S. distribution indefinitely, the firm is considering enlarging the devices to at least 3.25 mm in order to fit FDA's definition of an endosseous implant substantially equivalent to one legally marketed prior to the 1976 Medical Device Amendments. The warning letter advises the Swedish manufacturer of endosseous implants and dental instruments that until the firm demonstrates substantial equivalence, the 3.0 mm device will be denied entry into the U.S.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.